Rédaction Africa Links 24 with Lizzy Lawrence
Published on 2024-04-07 13:45:44
A controversial heart pump from Abiomed has shown promising results in reducing the number of deaths in severe heart attack patients, according to a recent randomized trial presented at the American College of Cardiology conference and published in the New England Journal of Medicine. The trial, which spanned 10 years and involved 355 patients in Denmark, Germany, and the United Kingdom, focused on patients who were admitted to the hospital with a heart attack and dangerously low blood flow, known as cardiogenic shock.
In the study, half of the patients received standard care, which typically included medication and in some cases life support, while the other half received Abiomed’s left-sided heart pump, known as the Impella, for a duration of 48 hours. The results revealed that 46% of patients in the device group died, compared to 59% in the standard care group. Additionally, 24% of patients in the device group experienced complications, such as serious bleeding and the need for kidney therapy, as opposed to 6% in the control group.
The findings from this trial have sparked interest and debate within the medical community, as the use of Abiomed’s heart pump has been met with controversy in the past. Despite the promising results in reducing mortality rates, concerns have been raised about the potential complications associated with the device. It is important to note that further research and clinical trials are needed to fully understand the benefits and risks of using the Impella heart pump in patients with severe heart attacks and cardiogenic shock.
The Impella heart pump works by assisting the left side of the heart in pumping blood, which can help improve blood flow and circulation in patients experiencing heart failure. By providing temporary support to the heart, the device aims to reduce the workload on the heart and improve overall cardiac function. While the results of this trial are promising, it is essential for healthcare providers and researchers to continue monitoring the long-term outcomes and safety of using the Impella heart pump in clinical practice.
Overall, the findings of this trial indicate that the use of Abiomed’s heart pump may offer a potential benefit in reducing mortality rates in patients with severe heart attacks and cardiogenic shock. However, more research is needed to fully understand the implications of using this device in clinical practice and to ensure the safety and efficacy of its use. As advancements in medical technology continue to evolve, it is crucial for healthcare providers to be informed about the latest research findings and treatment options available for patients with serious cardiac conditions.
